Jacob M Rosenberg1, Jordan V Price2, Gabriela Barcenas-Morales3, Lourdes Ceron-Gutierrez4, Sophie Davies4, Dinakantha S Kumararatne4, Rainer Döffinger5, Paul J Utz6. 1. Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, Calif. Electronic address: JakeRos@stanford.edu. 2. Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, Calif. 3. Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom; Laboratorio de Inmunologia, UNAM, FES-Cuautitlan, Cuautitlán Izcalli, Mexico. 4. Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom. 5. Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, United Kingdom; National Institute for Health Research (NIHR), Cambridge Biomedical Research Centre, Cambridge, United Kingdom. 6. Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, Calif; Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, Calif. Electronic address: PJUtz@stanford.edu.
Abstract
BACKGROUND: Anti-cytokine autoantibodies (ACAAs) are pathogenic in a handful of rare immunodeficiencies. However, the prevalence and significance of other ACAAs across immunodeficiencies have not yet been described. OBJECTIVE: We profiled ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and assessed the sensitivity and specificity of protein microarrays for ACAA identification and discovery. METHODS: Highly multiplexed protein microarrays were designed and fabricated. Blinded serum samples from a cohort of 58 immunodeficiency patients and healthy control subjects were used to probe microarrays. Unsupervised hierarchical clustering was used to identify clusters of reactivity, and after unblinding, significance analysis of microarrays was used to identify disease-specific autoantibodies. A bead-based assay was used to validate protein microarray results. Blocking activity of serum containing ACAAs was measured in vitro. RESULTS: Protein microarrays were highly sensitive and specific for the detection of ACAAs in patients with autoimmune polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent with those reported in the published literature. Protein microarray results were validated by using an independent bead-based assay. To confirm the functional significance of these ACAAs, we tested and confirmed the blocking activity of select ACAAs in vitro. CONCLUSION: Protein microarrays are a powerful tool for ACAA detection and discovery, and they hold promise as a diagnostic for the evaluation and monitoring of clinical immunodeficiency.
BACKGROUND: Anti-cytokine autoantibodies (ACAAs) are pathogenic in a handful of rare immunodeficiencies. However, the prevalence and significance of other ACAAs across immunodeficiencies have not yet been described. OBJECTIVE: We profiled ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and assessed the sensitivity and specificity of protein microarrays for ACAA identification and discovery. METHODS: Highly multiplexed protein microarrays were designed and fabricated. Blinded serum samples from a cohort of 58 immunodeficiencypatients and healthy control subjects were used to probe microarrays. Unsupervised hierarchical clustering was used to identify clusters of reactivity, and after unblinding, significance analysis of microarrays was used to identify disease-specific autoantibodies. A bead-based assay was used to validate protein microarray results. Blocking activity of serum containing ACAAs was measured in vitro. RESULTS: Protein microarrays were highly sensitive and specific for the detection of ACAAs in patients with autoimmune polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent with those reported in the published literature. Protein microarray results were validated by using an independent bead-based assay. To confirm the functional significance of these ACAAs, we tested and confirmed the blocking activity of select ACAAs in vitro. CONCLUSION: Protein microarrays are a powerful tool for ACAA detection and discovery, and they hold promise as a diagnostic for the evaluation and monitoring of clinical immunodeficiency.
Authors: Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland Journal: Blood Date: 2012-03-08 Impact factor: 22.113
Authors: Darragh Duffy; Vincent Rouilly; Valentina Libri; Milena Hasan; Benoit Beitz; Mikael David; Alejandra Urrutia; Aurélie Bisiaux; Samuel T Labrie; Annick Dubois; Ivo G Boneca; Cécile Delval; Stéphanie Thomas; Lars Rogge; Manfred Schmolz; Lluis Quintana-Murci; Matthew L Albert Journal: Immunity Date: 2014-03-20 Impact factor: 31.745
Authors: P Ghillani; C André; C Toly; A M Rouquette; D Bengoufa; P Nicaise; C Goulvestre; A Gleizes; M A Dragon-Durey; M A Alyanakian; P Chretien; S Chollet-Martin; L Musset; B Weill; C Johanet Journal: Autoimmun Rev Date: 2011-04-05 Impact factor: 9.754
Authors: U Dirksen; R Nishinakamura; P Groneck; U Hattenhorst; L Nogee; R Murray; S Burdach Journal: J Clin Invest Date: 1997-11-01 Impact factor: 14.808
Authors: Kanji Uchida; David C Beck; Takashi Yamamoto; Pierre-Yves Berclaz; Shuichi Abe; Margaret K Staudt; Brenna C Carey; Marie-Dominique Filippi; Susan E Wert; Lee A Denson; Jonathan T Puchalski; Diane M Hauck; Bruce C Trapnell Journal: N Engl J Med Date: 2007-02-08 Impact factor: 91.245
Authors: Takuro Sakagami; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Robert E Wood; Susan E Wert; Jeffrey A Whitsett; Bruce C Trapnell; Maurizio Luisetti Journal: N Engl J Med Date: 2009-12-31 Impact factor: 91.245
Authors: Anagha Malur; Mani S Kavuru; Irene Marshall; Barbara P Barna; Isham Huizar; Reema Karnekar; Mary Jane Thomassen Journal: Respir Res Date: 2012-06-14
Authors: Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: Tiffany Perkins; Jacob M Rosenberg; Carole Le Coz; Joseph T Alaimo; Melissa Trofa; Sureni V Mullegama; Richard J Antaya; Soma Jyonouchi; Sarah H Elsea; Paul J Utz; Eric Meffre; Neil Romberg Journal: J Allergy Clin Immunol Pract Date: 2017-03-09
Authors: Jakob Hjorth von Stemann; Andreas Stribolt Rigas; Lise Wegner Thørner; Daniel Guldager Kring Rasmussen; Ole Birger Pedersen; Klaus Rostgaard; Christian Erikstrup; Henrik Ullum; Morten Bagge Hansen Journal: PLoS One Date: 2017-06-30 Impact factor: 3.240
Authors: Elena N Savvateeva; Marina Yu Yukina; Nurana F Nuralieva; Marina A Filippova; Dmitry A Gryadunov; Ekaterina A Troshina Journal: Int J Mol Sci Date: 2021-05-23 Impact factor: 5.923